Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation.
The feasibility of development of transdermal delivery system of olanzapine utilizing natural oils as permeation enhancers was investigated. Penetration enhancing potential of corn (maize) oil, groundnut oil and jojoba oil on in vitro permeation of olanzapine across rat skin was studied. The magnitude of flux enhancement factor with corn oil, groundnut oil and jojoba oil was 7.06, 5.31 and 1.9 respectively at 5mg/ml concentration in solvent system. On the basis of in vitro permeation studies, eudragit based matrix type transdermal patches of olanzapine were fabricated using optimized concentrations of natural oils as permeation enhancers. All transdermal patches were found to be uniform with respect to physical characteristics. The interaction studies carried out by comparing the results of ultraviolet, HPLC and FTIR analyses for the pure drug, polymers and mixture of drug and polymers indicated no chemical interaction between the drug and excipients. Corn oil containing unsaturated fatty acids was found to be promising natural permeation enhancer for transdermal delivery of olanzapine with greatest cumulative amount of drug permeated (1010.68 μg/cm²/h) up to 24 h and caused no skin irritation. The fabricated transdermal patches were found to be stable. The pharmacokinetic characteristics of the final optimized matrix patch (T2) were determined after transdermal application to rabbits. The calculated relative bioavailability of TDDS was 113.6 % as compared to oral administration of olanzapine. The therapeutic effectiveness of optimized transdermal system was confirmed by tranquillizing activity in rotarod and grip mice model.
Rayat and Bahra Institute of Pharmacy, Sahauran, District Mohali, Punjab -140104, India.
Geeta
G
Aggarwal
Sanju
S
Dhawan
S L
SL
HariKumar
D000279:Administration, Cutaneous; D000818:Animals; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000737:chemistry* / Q000493:pharmacokinetics; D001682:Biological Availability; D001688:Biological Products / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry; D002626:Chemistry, Pharmaceutical / Q000379:methods; D005079:Excipients / Q000008:administration & dosage / Q000737:chemistry; D005260:Female; D008297:Male; D051379:Mice; D009821:Oils / Q000008:administration & dosage* / Q000737:chemistry; D000077152:Olanzapine; D010539:Permeability; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D012867:Skin / Q000187:drug effects* / Q000378:metabolism*; D012869:Skin Absorption / Q000187:drug effects; D057968:Transdermal Patch
D001688:Biological Products; D005079:Excipients; D009821:Oils; D001569:Benzodiazepines; D000077152:Olanzapine